GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (STU:35H) » Definitions » Inventories, Finished Goods

Homology Medicines (STU:35H) Inventories, Finished Goods : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Homology Medicines Inventories, Finished Goods?


Homology Medicines Inventories, Finished Goods Historical Data

The historical data trend for Homology Medicines's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Homology Medicines Inventories, Finished Goods Chart

Homology Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Finished Goods
Get a 7-Day Free Trial - - - - -

Homology Medicines Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Homology Medicines Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Homology Medicines (STU:35H) Business Description

Traded in Other Exchanges
Address
One Patriots Park, Bedford, MA, USA, 01730
Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Homology Medicines (STU:35H) Headlines

No Headlines